Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 547-557

  Quintás Cardama, Alfonso ^b   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

Leukemia; Nucleoside analogs; Troxacitabine

Indexed keywords

CAMPTOTHECIN; CYTARABINE; GEMCITABINE; IDARUBICIN; IMATINIB; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISONE; TOPOTECAN; TROXACITABINE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLISTER; BOLUS INJECTION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; GAIT DISORDER; HAND FOOT SYNDROME; HAND MOVEMENT; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY TUMOR; LEUKEMIA; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PHARMACODYNAMICS; PRURITUS; RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SKIN TIGHTNESS; SOFT TISSUE DISEASE; SOLID TUMOR; STEREOCHEMISTRY; STEREOISOMERISM; STOMATITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NUCLEOSIDES; STEREOISOMERISM;

EID: 34147191159     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.547     Document Type: Article

References (45)

1. BODEY GP, FREIREICH EJ, MONTO RW, HEWLETT JS: Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother. Rep. (1969) 53:59-66.
2. MOORE LE, BOUDINOT FD, CHU CK: Preclinical pharmacokinetics of β-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother. Pharmacol. (1997) 39:532-536.
3. KIM HO, AHN SK, ALVES AJ et al.: Asymmetric synthesis of 1,2-dioxolane-pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. (1992) 35(11):1987-1995.
4. MANSOUR TS, JIN H, WANG W et al.: Structure-activity relationship among a new class of antiviral and heterosubstituted 2′, 3′-dideoxynucleoside analogues. Nucleosides Nucleotides (1995) 14:627-635.
5. GROVE KL, GUO X, LIU SH, GAO Z, CHUCK, CHENG YC: Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. (1995) 55:3008-3011.
6. GOURDEAU H, CLARKE ML, OUELLET F et al.: Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid rumor cell lines. Cancer Res. (2001) 61:7217-7224.
7. OWENS JK, SHEWACH DS, ULLMAN B et al.: Resistance to 1-β-n-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. (1992) 52:2389-2393.
8. GATI WP, PATERSON AR, BELCH AR et al.: Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cyrarabine (araC). Leuk. Lymphoma (1998) 32:45-54.
9. DE BJS, STEPHENSON JJR, BAKER SD et al.: Troxacitabine, an L-stereoisomeric nucleoside analogue, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. (2002) 20(1):96-109.
10. GOURDEAU H, BIBEAU L, OUELLET F, CUSTEAU D, BERNIER L, BOWLIN T: Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and araC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother. Pharmacol. (2001) 47:236-240.
11. BOIVIN AJ, GOURDEAU H, MOMPARLER RL: Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. Cancer Invest. (2004) 22(1):25-29.
12. KRISHNAN P, LIOU JY, CHENG Y: Phosphorylation of pyrimidine L-deoxynudeoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J. Biol Chem. (2002) 277:31593-31600.
13. KRISHNAN P, FU Q LAM W, LIOU JY, DUTSHMAN G, CHENG YC: Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. (2002) 277:5453-5459.
14. KRISHNAN P, GULLEN EA, LAM W, DUTSCHMAN GE, GRILL SP, CHENG YC: Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J. Biol. Chem. (2003) 278:36726-36732.
15. GRANTS: Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. (1998) 72:197-233.
16. CHOU KM, KUKHANOVA M, CHENG YC: A novel action of human apurinic/ apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J. Biol. Chem. (2000) 275:31009-31015.
17. GROVE KL, CHENG YC: Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. (1996) 56(18):4187-4191.
18. LAM W, PARK SY, LEUNG CH, CHENG YC: Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxidty of L-configuration deoxycytidine analogs (troxacitabine and β-L- 2′,3′-dideoxy-2′,3′-didehydro-5- fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and β-D-arabinofuranosylcytosine). Mol. Pharmacol. (2006) 69(5):1607-1614.
19. KUKHANOVA M, LIU SH, MOZZHERIN D, LIN TS, CHU CK, CHENG YC: L- and D-enantiomers of 2′,3′-dodepxucutodome 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem. (1995) 270:23055-23059.
20. GRIEB P, KORONKIEWICZ M, SKIERSKI JS: Cytostatic and cytotoxic effects of (E)-2′-deoxy-2′-(fluoromethylene)-cytidine on a solid tumor and a leukemia cell line. Acta Biochim. Pol. (2000) 47:165-171.
21. SELEY KL: Tezacitabine Hoechst Marion Roussel. Curr. Opin. Investig. Drugs (2000) 1:135-140.
22. FINCH RA, LIU M, GRILL SP et al.: Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. (2000) 59:983-991.
23. GOURDEAU H, GENNE P, KADHIM S et al.: Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother. Pharmacol. (2002) 50:490-496.
24. KIM TE, PARK SY, HSU CH, DUTSCHMAN GE, CHENG YC: Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines. Mol. Pharmacol. (2004) 66(2):285-292.
25. SIU L, ATTARDO G, IZBICKA E et al.: Activity of (-)-2′deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann. Oncol. (1998) 9:885-891.
26. SCHWARTZ PM, HAGGERTY JG, CHENG YC: β-L-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol. Appl. Skin Physiol. (1998) 11(4-5):207-213.
27. KHADIM S, BOWLIN TL, WAUD WR et al.: Potent anti tumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. (1997) 57(21):4803-4810.
28. ATTARDO G, KADHIM S, ANGERS E, BIBEAU L, BOWLIN L: Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. Proc. Am. Assoc. Cancer Res. (1997) 38:100.
29. RABBANI SA, HARAKIDAS P, BOWLIN T, ATTARDO G: Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res. (1998) 58(15):3461-3465.
30. WEITMAN S, MARTY J, JOLIVET J, LOCAS C, VON HOFF DD: The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin. Cancer Res. (2000) 6:1574-1578.
31. ORSOLIC N, GILES FJ, GOURDEAU H et al.: Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br. J. Haematol. (2004) 124(6):727-738.
32. GOURDEAU H, LEBLOND L, HAMELIN B et al.: Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin. Cancer Res. (2004) 10:7692-7702.
33. BELANGER K, MOORE M, BAKER SD et al.: Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J. Clin. Oncol. (2002) 20:2567-2574.
34. CANOVA A, YEE L, BAKERS: A Phase I and pharmacokinetic study of β-L-dioxalo-cytidine (BCH-4556) administered weekly for three weeks every 28 days. Proc. Am. Soc. Clin. Oncol. (1999) 18:197.
35. STEPHENSON JRJ, BAKER SD, AYLESWORTH C: A Phase I safety and pharmacokinetic study of BCH-4556, a novel L-nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Ann. Oncol. (1998) 9(Suppl. 2):156
36. BAKER SD, STEPHENSON J, GOETZ A: Determinants affecting β-L-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in Phase I trials. Proc. Am. Soc. Clin. Oncol. (1999) 18:197.
37. DE BONO JS, STEPHENSON JJ, BAKER SD et al.: Troxacitabine, and L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. (2002) 20(1):96-109.
38. GILES FJ, CORTES JE, BAKER SD et al.: Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J. Clin. Oncol. (2001) 19(3):762-771.
39. GILES FJ, GARCIA-MANERO G, CORTES JE et al.: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J. Clin. Oncol. (2002) 20:656-664.
40. SACCHI S, KANTARJIAN HM, O'BRIEN S et al.: Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 86:2632-2641.
41. GILES FJ, FELDMAN EJ, ROBOZ GJ et al.: Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk. Res. (2003) 23:1091-1096.
42. GILES FJ, FADERL S, THOMAS DA et al.: Randomized Phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol. (2003) 21:1050-1056.
43. GILES FJ, KANTARJIAN HM, CORTES JE et al.: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol. (2003) 21:1722-1727.
44. ROBOZ G, GILES FJ, RITCHIE EK et al.: Phase I/II study of troxacitabine administered by continuous infusion in patients with refractory acute myeloid leukemia. J. Clin. Oncol. (2006) 25(1):10-15.
45. LEE CK, ROWINSKY EK, LI J et al.: Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clip. Cancer Res. (2006) 12(7):2158-2165.